MyMedicalRecords Terminates Agreement With WebMD, Will Refile Patent Infringement Complaint

MyMedicalRecords Terminates Agreement With WebMD, Will Refile Patent 
Infringement Complaint 
LOS ANGELES, CA -- (Marketwired) -- 09/03/13 --    MMRGlobal, Inc.
(OTCQB: MMRF) today announced that MyMedicalRecords, Inc., a wholly
owned subsidiary of MMRGlobal (collectively, "MMR"), has terminated
the written Agreement it signed with WebMD Health Corp. and WebMD
Health Services Group, Inc. (collectively, "WebMD") which MMR
announced on June 7, 2013, in connection with the dismissal of MMR's
patent infringement complaint. MMR is a leading provider of Personal
Health Records (PHRs) and electronic document management and imaging
systems for healthcare professionals. The action was originally filed
against WebMD on February 11, 2013, in the U. S. District Court for
the Central District of California, case number CV 13-00979
(ODW/SHx). As a material inducement for MMR to dismiss its complaint,
the parties signed the Agreement setting forth certain terms and
conditions including formal negotiations to resolve the matter
without the timing constraints imposed by the lawsuit.  
MMR and WebMD also specifically agreed that MMR would have the right
to refile the litigation without prejudice at any time. Since the
signing of the Agreement, the parties have worked to resolve the
matter in person and with legal counsel on both coasts without
results satisfactory to either party. However, since that time, MMR
also received an additional U.S. Patent, No. 8,498,883, entitled
"Method for Providing a User with a Service for Accessing and
Collecting Prescriptions," which it appears WebMD may also infringe.  
According to Robert H. Lorsch, MMRGlobal CEO, "The Agreement that we
dismiss the complaint to facilitate settlement may have been a
blessing in disguise because MMR has received at least one additional
patent to include in a complaint that was not issued at the time of
the original filing." 
Therefore, and based on a relationship with WebMD that goes back to a
Goldman Sachs introduction in 2007, MMR has decided that it is in its
best interest to terminate the Agreement and to refile its complaint
so that MMR can avail itself to the benefits of discovery and the
prospect of adding the "883" patent and other patents to the
complaint. Given that MMR invested nearly eight months in good faith
negotiations with WebMD, the door will always be open to a fair
negotiated resolution. 
MMR understands that PHRs are and will continue to be part of WebMD's
business plans and believes that WebMD infringes on one or more MMR
patents, which compels either a positive business relationship
between the companies or a Federal Court decision on the merits. MMR
further believes they will continue to be relevant to WebMD's
business based on Meaningful Use requirements starting in 2014.
Meaningful Use, mandated under the Health Information Technology for
Economic and Clinical Health Act ("HITECH"), includes core
requirements making Personal Health Records available to virtually
all Americans.  
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, professional organizations, and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents such as birth
certificates, passports, insurance policies, and wills anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images, and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January of 2009, the
Company acquired intellectual property biotech assets that included
anti-CD20 antibodies and data and samples from its
FavId(TM)/Specifid(TM) vaccine clinical trials for the treatment of
B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc.
visit www.mmrglobal.com. View demos and video tutorials of the
Company's products and services at www.mmrtheater.com. 
Forward-Looking Statements
 All statements in this press release that
are not strictly historical in nature, including, without limitation,
whether or not such statement relates directly to WebMD, and
intellectual property enforcement actions, infringement claims or
litigation, intellectual property licenses, and future performance,
management's expectations, beliefs, intentions, estimates, or
projections, constitute "forward-looking statements." Such
forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause MMR's actual results
to be materially different from historical results or from any
results expressed or implied by such forward-looking statements. Some
can be identified by the use of words (and their derivations) such as
"need," "possibility," "potential," "intend," "offer," "development,"
"if," "negotiate," "when," "begun," "believe," "achieve," "will,"
"estimate," "expect," "maintain," "plan," and "continue," or the
negative of these words. Actual outcomes and results of operations
and the timing of selected events may differ materially from the
results predicted, and any reported results should not be considered
as an indication of future performance. Such statements are
necessarily based on assumptions and estimates and are subject to
various risks and uncertainties, including those relating to the
possible invalidity of the underlying assumptions and estimates and
possible changes or developments in economic, business, industry,
market, legal, and regulatory circumstances, conditions, and actions
taken or omitted to be taken by third parties, including customers,
suppliers, business partners, potential licensees, competitors, and
legislative, judicial, and other governmental authorities and
officials. Factors that could cause or contribute to such differences
include but are not limited to unexpected outcomes with respect to
intellectual property enforcement actions, claims of intellectual
property infringement, and general intellectual property litigation;
our ability to maintain, develop, monetize, and protect our patent
portfolio for both MMR's health IT and biotechnology intellectual
property assets in the U.S. and internationally; the timing of
milestone payments in connection with licensing our intellectual
property; our ability to establish and maintain strategic
relationships; changes in our relationships with our licensees; the
risk MMR's products are not adopted or viewed favorably by the
healthcare community and consumer retail market; business prospects,
results of operations or financial condition; risks related to the
current uncertainty and instability in financial and lending markets
including global economic uncertainties; the timing and volume of
sales and installations; the length of sales cycles and the
installation process; the market's acceptance of new product and
service introductions; competitive 
product offerings and promotions;
changes in government laws and regulations including the 2009 HITECH
Act and changes in Meaningful Use and the 2010 Affordable Care Act;
future changes in tax legislation and initiatives in the healthcare
industry; undetected errors in our products; the possibility of
interruption at our data centers; risks related to third party
vendors; risks related to obtaining and integrating third-party
licensed technology; risks related to a security breach by third
parties; risks associated with recruitment and retention of key
personnel; other litigation matters; uncertainties associated with
doing business internationally across borders and territories; and
additional risks discussed in MMRGlobal's filings with the Securities
and Exchange Commission. MMR is providing this information as of the
date of this release and, except as required by applicable law, does
not undertake any obligation to update any forward-looking statements
contained in this release as a result of new information, future
events, or otherwise.  
CONTACT: 
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033